JURA Bio and Syena partner to develop TCR-based therapies
Pharmaceutical Technology
SEPTEMBER 22, 2023
JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.
Pharmaceutical Technology
SEPTEMBER 22, 2023
JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.
Pharmaceutical Technology
SEPTEMBER 21, 2023
Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 30, 2023
Biostax and Immgenuity have entered into an agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.
Pharmaceutical Technology
AUGUST 23, 2023
Revive has begun the development of a next-generation formulation of Bucillamine to treat public health emergencies.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies.
Worldwide Clinical Trials
AUGUST 15, 2023
Selecting the right CRO to partner with on your development program is a pivotal decision that can shape the trajectory of your product’s development. You’ll have direct access to our subject matter experts and your counterparts as needed for truly collaborative development. You have the oversight you need.
Pharmaceutical Technology
SEPTEMBER 26, 2023
Novo Nordisk has signed an agreement with Valo Health for the discovery and development of new therapies to treat cardiometabolic diseases.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.
Let's personalize your content